Business Description
SciClone Pharmaceuticals (Holdings) Ltd
ISIN : KYG4271B1023
Compare
Compare
Traded in other countries / regions
06600.Hong KongSCCPF.USA IPO Date
2021-03-03Description
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, including oncology and severe infection. Its products are Zadaxin, Zometa, Oravig, Endoxan, Angiomax, and others. It derives revenue from sales of products.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 67.72 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | 21.6 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 12.11 | |||||
Beneish M-Score | -2.67 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.5 | |||||
3-Year EBITDA Growth Rate | 12.5 | |||||
3-Year EPS without NRI Growth Rate | 12.8 | |||||
3-Year FCF Growth Rate | 35.6 | |||||
3-Year Book Growth Rate | 118.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 74.9 | |||||
9-Day RSI | 71.14 | |||||
14-Day RSI | 71.44 | |||||
6-1 Month Momentum % | 44.27 | |||||
12-1 Month Momentum % | 77.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.94 | |||||
Quick Ratio | 4.5 | |||||
Cash Ratio | 3.18 | |||||
Days Inventory | 86.34 | |||||
Days Sales Outstanding | 101.32 | |||||
Days Payable | 68.39 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.08 | |||||
Dividend Payout Ratio | 0.2 | |||||
5-Year Yield-on-Cost % | 2.08 | |||||
3-Year Average Share Buyback Ratio | 2.6 | |||||
Shareholder Yield % | 14.41 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.67 | |||||
Operating Margin % | 39.84 | |||||
Net Margin % | 35.55 | |||||
FCF Margin % | 42.04 | |||||
ROE % | 36.85 | |||||
ROA % | 26.73 | |||||
ROIC % | 93.99 | |||||
ROC (Joel Greenblatt) % | 219.01 | |||||
ROCE % | 38.02 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 9.95 | |||||
PE Ratio without NRI | 9.85 | |||||
Price-to-Owner-Earnings | 11.41 | |||||
PEG Ratio | 0.49 | |||||
PS Ratio | 3.53 | |||||
PB Ratio | 3.29 | |||||
Price-to-Tangible-Book | 3.74 | |||||
Price-to-Free-Cash-Flow | 8.38 | |||||
Price-to-Operating-Cash-Flow | 7.91 | |||||
EV-to-EBIT | 6.77 | |||||
EV-to-Forward-EBIT | 5.44 | |||||
EV-to-EBITDA | 6.77 | |||||
EV-to-Forward-EBITDA | 5.34 | |||||
EV-to-Revenue | 2.74 | |||||
EV-to-Forward-Revenue | 1.69 | |||||
EV-to-FCF | 6.51 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.49 | |||||
Price-to-Graham-Number | 1.28 | |||||
Price-to-Net-Current-Asset-Value | 3.96 | |||||
Price-to-Net-Cash | 7.2 | |||||
Earnings Yield (Greenblatt) % | 14.77 | |||||
FCF Yield % | 12.3 | |||||
Forward Rate of Return (Yacktman) % | 27.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SciClone Pharmaceuticals (Holdings) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | 3,451.546 | ||
EPS (TTM) (HK$) | 1.881 | ||
Beta | 0 | ||
Volatility % | 49.36 | ||
14-Day RSI | 71.44 | ||
14-Day ATR (HK$) | 0.051152 | ||
20-Day SMA (HK$) | 18.653 | ||
12-1 Month Momentum % | 77.52 | ||
52-Week Range (HK$) | 8.75 - 18.72 | ||
Shares Outstanding (Mil) | 630.3 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
SciClone Pharmaceuticals (Holdings) Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
SciClone Pharmaceuticals (Holdings) Ltd Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
SciClone Pharmaceuticals (Holdings) Ltd Frequently Asked Questions
What is SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600)'s stock price today?
The current price of HKSE:06600 is HK$18.72. The 52 week high of HKSE:06600 is HK$18.72 and 52 week low is HK$8.75.
When is next earnings date of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600)?
The next earnings date of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is .
Does SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) pay dividends? If so, how much?
The Dividend Yield %  of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is 2.08% (As of Today), Highest Dividend Payout Ratio of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) was 0.23. The lowest was 0.2. And the median was 0.22. The  Forward Dividend Yield % of SciClone Pharmaceuticals (Holdings) Ltd(HKSE:06600) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |